JP2011219469A - Preventing and ameliorating agent for urinary tract infection - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a preventing and ameliorating agent for urinary tract infection, suppressing side effects and development of drug-resistant strain and easily available and, accordingly, usable for preventive purpose over a long time.SOLUTION: The preventing and ameliorating agent for urinary tract infection contains D-(+)-mannose. The D-(+)-mannose is preferably derived from a vegetable hemicellulose.

Description

  The present invention relates to a urinary tract infection prevention / amelioration agent containing D-(+)-mannose, a food / beverage product, feed and pet food containing the urinary tract infection prevention / amelioration agent.

  Urinary tract infection is a disease that causes inflammation by infecting bacteria in the urinary tract (urinary tract) such as the urethra, bladder, and kidney, and is a general term for cystitis, urethritis, pyelonephritis, and the like. Symptoms include frequent urination, micturition pain, urine turbidity, residual urine sensation, and discomfort around the bladder. If you suffer from urinary tract infections, the average duration of symptoms for 6.1 days, the average daily activity limit for 2.4 days, the average work limit for 1.2 days, the average bed for 0.4 days, etc. It occurs and is affected by daily life (Non-patent Document 1).

  Urinary tract infection is one of the most frequently occurring bacterial infections, especially in women, and in the United States, the prevalence of women's urinary tract infection is 60% in their lifetime. It has been reported. Among urinary tract infections, about half of acute cystitis is said to recur within one year (Non-patent Document 2).

  As a treatment method for urinary tract infections, administration of antibiotics such as new quinolone drugs is common (Non-patent Document 1). However, when such antibiotics are used, side effects and the development of resistant bacteria are problematic. In addition, due to amendments to the Pharmaceutical Affairs Law, prescriptions are required for the use of such antibiotics, so daily use such as preventive or long-term intake may not be possible. . In addition, urinary tract infection is a disease that should be consulted originally, but hesitant to visit the urology department and sometimes chooses natural healing.

  D-(+)-mannose is a component of a sugar chain on the cell surface and plays an important role in communication between cells. Furthermore, it has been found to inhibit colonization of harmful bacteria such as Escherichia coli and Salmonella in the intestinal tract (see, for example, Patent Document 1). However, it has not been known that when D-(+)-mannose is ingested, it has an effect of preventing and improving urinary tract infections.

JP-A-8-38064

Edited by Japanese Society for Infectious Diseases and Japanese Society of Chemotherapy, “Guidelines for Using Antibacterial Drugs”, 2001 Noriko Tsuchiya, Yamanashi journaling, Vol. 4, No. 1, 2005

  An object of the present invention is to provide an agent for preventing and improving urinary tract infections that can suppress side effects and the development of resistant bacteria and can be used prophylactically for a long period of time because it is easily available.

As a result of intensive studies to solve such problems, the present inventors found for the first time that D-(+)-mannose has an effect of preventing and further improving urinary tract infections, The present invention has been reached.
That is, the gist of the present invention is as follows.
(1) A urinary tract infection prevention / amelioration agent characterized by containing D-(+)-mannose.
(2) The urinary tract infection prevention / amelioration agent according to (1), wherein D-(+)-mannose is derived from plant hemicellulose.
(3) The agent for preventing or improving urinary tract infection according to (1) or (2), wherein the plant hemicellulose contains at least one selected from mannan, glucomannan and galactomannan as a constituent component.
(4) The urinary tract infection prevention / amelioration agent according to (1) to (3), wherein the plant is at least one selected from palm, coconut, and konjac.
(5) The agent for preventing and improving urinary tract infections according to (1) to (4), wherein D-(+)-mannose is obtained by hydrolyzing plant hemicellulose.
(6) A food or drink comprising the urinary tract infection prevention / amelioration agent according to any one of (1) to (5).
(7) A feed comprising the urinary tract infection prevention / amelioration agent according to any one of (1) to (5).
(8) A pet food comprising the urinary tract infection prevention / amelioration agent according to any one of (1) to (5).

  The agent for improving and preventing urinary tract infection of the present invention can prevent or suppress side effects and the development of resistant bacteria. In addition, since it is easily available, it can be used prophylactically over a long period of time. Furthermore, by ingesting food / beverage products, feed, and pet food containing the urinary tract infection prevention / amelioration agent of the present invention, there is a remarkable effect that urinary tract infections of humans and animals can be prevented and improved.

Hereinafter, the present invention will be described in detail.
The agent for improving and preventing urinary tract infection of the present invention contains D-(+)-mannose.

  D-(+)-mannose is a kind of hexasaccharide. D-(+)-mannose is widely present in nature in the form of a polysaccharide, and among them, it is abundant in plant hemicellulose.

  The method for obtaining D-(+)-mannose used in the present invention is not particularly limited, a method obtained by hydrolyzing plant hemicellulose or microbial polysaccharide, a method obtained by enzymatic or chemical isomerization of glucose or fructose, mannitol And the like, and the like. Among these, it is most preferable to use D-(+)-mannose obtained by hydrolyzing plant hemicellulose from the viewpoint of safety and cost. When the plant hemicellulose is hydrolyzed, it can be hydrolyzed using an acid, an alkali or an enzyme, or can be hydrolyzed in a high temperature and high pressure environment. Of these, it is most preferable to obtain D-(+)-mannose by hydrolysis using an enzyme in that there are few by-products, there are few restrictions on the equipment in the hydrolysis process, and there are few environmental loads. .

  The hemicellulose of the plant is not particularly limited, and examples thereof include mannan, glucomannan, galactomannan and the like as constituent components. Among these, mannan and glucomannan are more preferable from the viewpoint of easily purifying D-(+)-mannose. Furthermore, mannan is most preferable from the viewpoint of containing a large amount of D-(+)-mannose. In the present invention, the plant hemicellulose refers to a polysaccharide excluding cellulose among those contained in the plant cell wall.

  When mannan is used when hydrolyzing plant hemicellulose to obtain D-(+)-mannose, the raw material of mannan is not particularly limited, but palm (oil palm), coconut palm, elephant palm, coffee, cyhailan, Examples include konjac potatoes. Among these, palm is preferable from the viewpoint of containing a large amount of mannan, and the palm core in palm is most preferable.

  In order to hydrolyze plant hemicellulose, for example, an enzyme such as mannanase or galactomannanase is allowed to act on hemicellulose of a plant such as palm kernel, coconut palm, coffee bean, guar bean (guar gum), and konjac potato. The treatment is performed at ˜70 ° C. for 2 to 72 hours.

  D-(+)-mannose obtained by the above means is a liquid composition and usually contains many impurities. In the present invention, the liquid composition may be used as it is, but from the viewpoint of avoiding a large amount of ingestion, it may be purified and purified or purified. In order to purify or solidify D-(+)-mannose, known techniques such as solid-liquid separation, resin purification, membrane purification, concentration, spray drying, freeze drying, and crystallization are used. it can.

  Although content of D-(+)-mannose in the urinary tract infection prevention improving agent of this invention is not specifically limited, It is preferable that it is 10 mass% or more, and it is more preferable that it is 30 mass% or more. If the D-(+)-mannose content is less than 10% by mass, it may be necessary to take a large amount of a urinary tract infection prevention / amelioration agent for the urinary tract infection prevention / improvement effect.

  The basis for the content of D-(+)-mannose described above lies in the amount of D-(+)-mannose ingested daily. That is, the urinary tract infection prevention / amelioration agent of the present invention is prepared so that the content of D-(+)-mannose taken daily is 100 mg to 10 g, and further 500 mg to 5 g. It is preferable.

  The urinary tract infection prevention / amelioration agent of the present invention can be formulated into various dosage forms by using known and commonly used carriers in the pharmaceutical field as long as the effects of the present invention are not impaired. Examples of the dosage form include solid preparations such as tablets, granules, fine granules, powders, capsules and pills; and liquid preparations such as solutions, suspensions and emulsions. Especially, it is preferable to set it as a fine granule or a powder from a viewpoint of the ease of taking.

  Examples of the carrier used for preparing a solid preparation include excipients, binders, disintegrants, lubricants, flavoring agents, and coloring agents. Examples of excipients include lactose, sucrose, glucose, mannitol, sorbit, dextrin, starch, crystalline cellulose, carboxymethylcellulose, hydroxypropylcellulose, dextran, pullulan, anhydrous silicic acid, calcium phosphate, calcium carbonate, calcium sulfate and the like. . Examples of the binder include crystalline cellulose, sucrose, mannitol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, gum arabic, dextran, pullulan, water, ethanol and the like. Examples of the disintegrant include starch, carboxymethyl cellulose, hydroxypropyl cellulose, dextrin, and crystalline cellulose. Examples of the lubricant include stearic acid and metal salts thereof, talc, boric acid, fatty acid sodium salt, sodium lauryl sulfate, magnesium lauryl sulfate, and anhydrous silicic acid. Examples of flavoring agents include sucrose, orange peel, citric acid, and tartaric acid.

  Examples of the carrier used for preparing the liquid preparation include a buffer, a stabilizer, a flavoring agent and the like. Examples of the buffer include citrate and succinate. Examples of the stabilizer include lecithin, gum arabic, gelatin, and methylcellulose. Examples of the flavoring agent include the same flavoring agents used in preparing the oral solid preparation.

  Moreover, the urinary tract infection prevention improving agent of this invention may contain the chemical | medical agent which has other medicinal effects, such as a lactic acid bacteria formulation, in the range which does not impair the effect of this invention. Thereby, effects other than the urinary tract infection prevention effect can coexist, and the urinary tract infection prevention improvement effect can be further improved.

  The method of ingesting the urinary tract infection prevention / ameliorating agent of the present invention is not particularly limited, but it is preferably ingested by oral administration from the viewpoint of easy administration. For oral administration, for example, the above-mentioned carrier and the like are added to the urinary tract infection prevention / amelioration agent, and then granulated, granular, tablet, capsule, gel, paste, milk, What is necessary is just to shape | mold in the form suitable for oral administration, such as a turbid form and a liquid form. The urinary tract infection prevention / amelioration agent of the present invention includes, for the purpose of improving the taste, sugars, sugar alcohols, salts, fats and oils, amino acids, organic acids, fruit juices as long as the effects of the present invention are not impaired. , Vegetable juice, fragrance, alcohols, glycerin and the like.

  Moreover, the urinary tract infection prevention improving agent of this invention may be made into food-drinks by making it contain in the existing drink or foodstuff, and you may attach | subject to oral administration. Examples of existing beverages or foods include processed noodles such as udon and pasta; processed meat products such as ham and sausage; processed fishery products such as kamaboko and chikuwa; processed milk products such as butter, powdered milk and fermented milk; Desserts such as ice cream; processed foods such as breads, confectionery, and seasonings; and beverages such as soft drinks, alcoholic beverages, fruit juice beverages, vegetable juice beverages, milk beverages, carbonated beverages, and coffee beverages Is mentioned.

  In the case of making a food or drink by incorporating the urinary tract infection prevention improving agent of the present invention into an existing beverage or food, the form of the urinary tract infection prevention improving agent is not particularly limited, and in beverages, gummies, candy, etc. Can be used as a liquid urinary tract infection prevention / amelioration agent, and for tablets, granules, capsules, etc., a powdery urinary tract infection prevention / amelioration agent can be used.

  Although content of D-(+)-mannose in the food / beverage products of this invention is not specifically limited, It is preferable that it is 0.1 mass% or more, and it is more preferable that it is 1 mass% or more. If the D-(+)-mannose content is less than 0.1% by mass, a large amount of intake may be required for the effect of preventing and improving urinary tract infection. In addition, the basis of content of D-(+)-mannose in food-drinks exists in the quantity of D-(+)-mannose ingested on the above-mentioned 1st.

  For example, when a human having a body weight of about 60 kg ingests the food / beverage product containing the urinary tract infection prevention / amelioration agent of the present invention, the intake amount as D-(+)-mannose is 1 It is preferably ingested so as to be about 0.1 to 10 g per day.

  The agent for improving and preventing urinary tract infection of the present invention can exhibit a high effect of preventing and improving urinary tract infection not only for humans but also for animals. Therefore, the urinary tract infection prevention / amelioration agent of the present invention may be contained in animal feed or pet food and given for oral administration.

  The feed of the present invention refers to the urinary tract infection prevention and improvement agent of the present invention, for example, grains such as corn, wheat, barley and rye, bran such as bran and rice bran, corn such as corn gluten meal and corn jam meal. Manufactured by blending animal feed such as milk, skim milk powder, whey, fish, bone meal, yeast such as brewer's yeast, calcium such as calcium phosphate and calcium carbonate, vitamins, oils and fats, amino acids, saccharides, etc. can do. As a form of feed, it can be used for pet food, livestock feed, feed for cultured fish, and the like. Moreover, when using as pet food, even if it uses the same form (for example, processed noodle, processed meat product, etc.) as the said food-drinks, there is no problem.

  The content of D-(+)-mannose in the feed or pet food of the present invention is not particularly limited, but is preferably 0.1% by mass or more, and more preferably 1% by mass or more. If the D-(+)-mannose content is less than 0.1% by mass, it may be necessary to ingest a large amount of the feed or pet food in order to prevent and improve urinary tract infections. The basis for the content of D-(+)-mannose in feed and pet food lies in the amount of D-(+)-mannose ingested on the aforementioned day.

  The feed or pet food containing the urinary tract infection prevention / amelioration agent of the present invention has an intake of D-(+)-mannose of about 60 kg per day, for example, when the weight of the subject animal is about 60 kg. It is preferable to ingest so that it may become 0.1-10g.

  A high urinary tract infection prevention / improvement effect can be expressed by allowing humans and animals to ingest the urinary tract infection prevention / amelioration agent, food / beverage product, feed, and pet food of the present invention.

  Hereinafter, the present invention will be specifically described with reference to Examples and Comparative Examples.

(Example 1)
To 1 kg of palm kernel meal obtained by crushing and squeezing palm kernel, 5 g of mannanase (manufactured by Shinnippon Chemical Co., Ltd., trade name “Sumiteam AC”), 5 L of water and 20 g of oxalic acid are added and reacted at 60 ° C. for 48 hours. The enzyme was inactivated. Thereafter, 50 g of diatomaceous earth was added, and suction filtration was performed using a filter paper to obtain a clear filtrate. The filtrate was passed through a strongly acidic cation exchange resin (Mitsubishi Chemical Corporation, resin name: Diaion SK1B), and then passed through a weakly basic anion exchange resin (Mitsubishi Chemical Corporation, resin name: Diaion WA10). After removing the ionic substance by liquid, the solution was concentrated under reduced pressure with an evaporator to obtain a urinary tract infection prevention / amelioration agent containing 43% by mass of D-(+)-mannose.
(Urine tract infection improvement trial)
Fifteen female subjects with high cystitis recurrence frequency were given 2.33 g [D-(+)-mannose intake: 1 g] of the urinary tract infection prevention / amelioration agent obtained in Example 1 in the morning and evening. It was taken orally with 100 g of water twice a day. Ingestion was continued for half a year, and changes in the recurrence frequency of cystitis were examined.
The evaluation was performed in the following five stages by comparing before ingestion and after ingestion.
+2: Cystitis almost disappeared +1: Cystitis became somewhat difficult to develop 0: No change -1: Cystitis was slightly more likely to develop -2: Cystitis became easier to develop The evaluation results are shown in Table 1. In this evaluation, three persons interrupted the intake of the urinary tract infection prevention / amelioration agent on the way.

  As is clear from Table 1, it was found that urinary tract infections can be prevented and improved by taking a urinary tract infection prevention / amelioration agent containing D-(+)-mannose.

(Example 2)
Preparation of drink agent Urinary tract infection prevention and improvement agent obtained in Example 1 1500 mg
Ascorbic acid (BASF Takeda Vitamin Co., Ltd., trade name “L-ascorbic acid (vitamin C)”) 500 mg
L-cysteine (Kyowa Hakko Bio, trade name “L-cysteine hydrochloride Kyowa”) 50 mg
Pyridoxine hydrochloride (BASF Takeda Vitamin Co., Ltd., trade name “Vitamin B6”) 40 mg
Riboflavin (BASF Takeda Vitamin Co., Ltd., trade name “Riboflavin FP”) 10 mg
Biotin (DSM Nutrition, trade name “Biotin (Crystal)”) 0.05mg
Aspartame (Ajinomoto Healthy Supply, trade name “PAL SWEET DIET”) 5mg
Citric acid (trade name “citric acid (crystal)” manufactured by Iwata Chemical Industry Co., Ltd.) 100 mg
Lemon flavor (product name “Lemon Essence” manufactured by Pioneer Planning Co., Ltd.) 0.2ml
The above ingredients were dissolved in purified water to prepare a 200 ml drink.

(Example 3)
Preparation of soft capsule 200 mg of urinary tract infection prevention and improvement agent obtained in Example 1
Olive oil (Summit Oil Co., Ltd., trade name "Extra Virgin Olive Oil") 250mg
Glycerin fatty acid ester (trade name “Poem S”, manufactured by Riken Vitamin Co., Ltd.) 25mg
Beeswax (Miki Chemical Industry Co., Ltd., trade name “Beat Wax”) 25mg
The above ingredients and gelatin were mixed to obtain 500 mg of soft capsule as a whole.

Example 4
Preparation of juice 5 g of urinary tract infection prevention and improvement agent obtained in Example 1, 200 ml of concentrated cranberry juice (manufactured by OceanSpray ITG, trade name “Cranberry Concentrate”) and 800 ml of tap water are mixed and mixed well. 1 L of cranberry juice having an effect to prevent and improve road infection was obtained. There was no significant change in taste, smell or touch, and there was no effect on the flavor of cranberries.

(Example 5)
Preparation of candy 300 g of sugar, 250 g of syrup, and 100 g of the urinary tract infection prevention / amelioration agent obtained in Example 1 were dissolved by heating, boiled in a pan at 150 ° C., then transferred to a cooling plate and allowed to cool. Further kneading. This kneaded product was molded using a stamping molding machine (trade name “Stamping Machine MPM30” manufactured by Mihama Seisakusho Co., Ltd.) to obtain 120 candy having a mass of 4 g.

(Example 6)
Preparation of Dog Food A dry dog food for preventing urinary tract infection was produced by the following composition and procedure.
30 parts by weight of corn, 30 parts by weight of wheat flour, 17 parts by weight of defatted soybeans, 10 parts by weight of meat meal, 10 parts by weight of chicken meal, 1 part by weight of vitamin mineral mix, and 2 parts by weight of the composition of Example 1 were mixed and pulverized. . Thereafter, the size was adjusted using a sieve having an opening of 1 mm to obtain a composition. Water was added to the obtained composition so that the solid content concentration was about 27% by mass, and then extrusion processing was performed using a cooking extruder equipped with an 8 mm circular die to obtain a swollen product. It was. The obtained expanded product is dried at 120 ° C. for 20 minutes by a belt dryer, and then 5 parts by mass of soybean oil is sprayed on 95 parts by mass of the expanded product to obtain a dry dog food for preventing urinary tract infections. It was. This dry dog food contained 0.73% by mass of D-mannose.

  100 g of the dry dog food obtained in Example 6 was fed to a dog weighing 15 kg with a high recurrence frequency of cystitis. As a result, the frequency of urination decreased, and the effect of preventing urinary tract infection was observed in dogs as in humans.

Claims (8)

  An agent for preventing and improving urinary tract infection, comprising D-(+)-mannose.   The agent for preventing and improving urinary tract infection according to claim 1, wherein D-(+)-mannose is derived from plant hemicellulose.   The urinary tract infection prevention and improvement agent according to claim 1 or 2, wherein the plant hemicellulose contains at least one selected from mannan, glucomannan, and galactomannan as a constituent component.   The urinary tract infection prevention / amelioration agent according to any one of claims 1 to 3, wherein the plant is at least one selected from palm, coconut palm, and konjac potato.   The agent for preventing and improving urinary tract infection according to any one of claims 1 to 4, wherein D-(+)-mannose is obtained by hydrolyzing plant hemicellulose.   A food / beverage product comprising the urinary tract infection prevention / amelioration agent according to claim 1.   A feed comprising the urinary tract infection preventing / ameliorating agent according to any one of claims 1 to 5. A pet food comprising the urinary tract infection prevention / amelioration agent according to any one of claims 1 to 5.